1. Determinants of Summiting Success and Acute Mountain Sickness on Mt Kilimanjaro (5895m) 
Andrew J. Davies, MBChB, BSc (Hons), Nicholas S. Kalson, BSc, (Hons), Suzy Stokes, MBChB, (Hons), Mark D. Earl, MRes, Adam G. Whitehead, BSc, (Hons), Hannah Frost, BSc, (Hons), Ian Tyrell-Marsh, MBChB, (Hons), Jon Naylor, MBChB, MRCP 
Wilderness & Environmental Medicine 
Volume 20, Issue 4, Pages (December 2009)
DOI: /
Copyright © 2009 Wilderness Medical Society Terms and Conditions

2. Figure 1
Schematic of subject progression up Mt Kilimanjaro. The 2 ascent profiles (4-day ascent and 5-day ascent) were not equally used, and loss to follow-up occurred at each stage. Of the 281 trekkers recruited, 241 were followed up at 3700m, of which 148 spent a second night at this altitude (5 days). One hundred and forty-three of the 5-day cohort were followed up at 4700m and 117 on summit day. On the 4-day route 79 were followed up at 4700m, of which 64 were seen on the summit day.
Wilderness & Environmental Medicine  , DOI: ( / )
Copyright © 2009 Wilderness Medical Society Terms and Conditions

3. Figure 2
Mean acute mountain sickness scores varying with altitude on Mt Kilimanjaro. Significant differences between 5-day ascent profile climbers taking acetazolamide (AZ) and those not taking acetazolamide at 3700m (*) and 4700m (**) are shown on the graph (P=.02 and .04, respectively).
Wilderness & Environmental Medicine  , DOI: ( / )
Copyright © 2009 Wilderness Medical Society Terms and Conditions